Compare Amylx Pharmaceuticals Inc (AMLX) vs TKO Group Holdings Inc (TKO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs TKO Group Holdings Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while TKO Group Holdings Inc trades at $184.36 (market cap $13.82B). The key difference: TKO Group Holdings Inc is far larger — about 7× Amylx Pharmaceuticals Inc's market cap, and TKO Group Holdings Inc pays a 1.69% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | TKO | |
|---|---|---|
Market Cap | $1.98B | $13.82B |
Sector | Health | Technology |
52-Week High | $18.70 | $224.96 |
52-Week Low | $7.64 | $155.61 |
Enterprise Value | $1.70B | $18.00B |
Dividend Yield | — | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
TKO trades at $184.4, down 2.01% today, with a bearish technical signal but strong analyst support. Recent earnings show a Q1 2026 beat but Q3 and Q4 2025 misses, while revenue grew to $4.74B in 2025. The company completed an $800 million share repurchase and announced a dividend, reflecting financial strength. Valuation ratios like P/E of 68.55 are elevated, but profitability margins improved.
Outlook is mixed: bullish analyst consensus with a $234 price target suggests upside, but high valuation and recent earnings volatility pose risks. Growth in live events and partnerships, like the UFC-Paramount deal, offers opportunities, yet execution and market sentiment remain key watchpoints for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →
